Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsTommaso Clemente, Antonella Castagna, Emanuele Focà et al.|BMJ Open|2024Cited by 21
Polypharmacy, anticholinergic burden and drug–drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registryMaria Mazzitelli, Laura Comi, Maurizio Zazzi et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 7
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO RegistryDaniele Armenia, Alessio Bellucci, Maurizio Zazzi et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 6
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO RegistryTommaso Clemente, Vincenzo Spagnuolo, Riccardo Lolatto et al.|International Journal of Antimicrobial Agents|2024Cited by 3